The Experts below are selected from a list of 5511 Experts worldwide ranked by ideXlab platform

Kristina Tröster - One of the best experts on this subject based on the ideXlab platform.

  • 5 day cefixime therapy for bacterial pharyngitis and or tonsillitis comparison with 10 day Penicillin V therapy
    Infection, 1995
    Co-Authors: Dieter Adam, Ulrike Hostalek, Kristina Tröster
    Abstract:

    In an open, controlled, randomized multicenter study, 160 children suffering from pharyngitis and/or tonsillitis were treated with either 8 mg cefixime/kg body weight once daily for 5 days or 20,000 I.U. Penicillin V/kg body weight t.i.d. for 10 days. One hundred fifty-one children were eValuable for clinical efficacy. In the cefixime group, 65 (86.7%) children were cured, seVen (9.3%) were significantly improVed, one (1.3%) relapsed and in two (2.7%) therapy failed. Of the patients treated with Penicillin V, 69 (90.8%) were cured, fiVe (6.6%) improVed, one (1.3%) relapsed and in one (1.3%) therapy failed. Elimination of initial pathogens occurred in 57 (82.6%) patients treated with cefixime and in 60 (88.2%) treated with Penicillin V. At 3 to 4 weeks after the end of treatment, six relapses were seen in the cefixime group and eight in the Penicillin V group. Mild-to-moderate adVerse eVents that were possibly related to the medication were seen in four children treated with cefixime and in fiVe treated with Penicillin V.

  • 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: Comparison with 10-day Penicillin V therapy
    Infection, 1995
    Co-Authors: Dieter Adam, Ulrike Hostalek, Kristina Tröster
    Abstract:

    In an open, controlled, randomized multicenter study, 160 children suffering from pharyngitis and/or tonsillitis were treated with either 8 mg cefixime/kg body weight once daily for 5 days or 20,000 I.U. Penicillin V/kg body weight t.i.d. for 10 days. One hundred fifty-one children were eValuable for clinical efficacy. In the cefixime group, 65 (86.7%) children were cured, seVen (9.3%) were significantly improVed, one (1.3%) relapsed and in two (2.7%) therapy failed. Of the patients treated with Penicillin V, 69 (90.8%) were cured, fiVe (6.6%) improVed, one (1.3%) relapsed and in one (1.3%) therapy failed. Elimination of initial pathogens occurred in 57 (82.6%) patients treated with cefixime and in 60 (88.2%) treated with Penicillin V. At 3 to 4 weeks after the end of treatment, six relapses were seen in the cefixime group and eight in the Penicillin V group. Mild-to-moderate adVerse eVents that were possibly related to the medication were seen in four children treated with cefixime and in fiVe treated with Penicillin V.

  • 5 day cefixime therapy for bacterial pharyngitis and or tonsillitis comparison with 10 day Penicillin V therapy cefixime study group
    Infection, 1995
    Co-Authors: Dieter Adam, Ulrike Hostalek, Kristina Tröster
    Abstract:

    In an open, controlled, randomized multicenter study, 160 children suffering from pharyngitis and/or tonsillitis were treated with either 8 mg cefixime/kg body weight once daily for 5 days or 20,000 I.U. Penicillin V/kg body weight t.i.d. for 10 days. One hundred fifty-one children were eValuable for clinical efficacy. In the cefixime group, 65 (86.7%) children were cured, seVen (9.3%) were significantly improVed, one (1.3%) relapsed and in two (2.7%) therapy failed. Of the patients treated with Penicillin V, 69 (90.8%) were cured, fiVe (6.6%) improVed, one (1.3%) relapsed and in one (1.3%) therapy failed. Elimination of initial pathogens occurred in 57 (82.6%) patients treated with cefixime and in 60 (88.2%) treated with Penicillin V. At 3 to 4 weeks after the end of treatment, six relapses were seen in the cefixime group and eight in the Penicillin V group. Mild-to-moderate adVerse eVents that were possible related to the medication were seen in four children treated with cefixime and in fiVe treated with Penicillin V.

Dieter Adam - One of the best experts on this subject based on the ideXlab platform.

  • 5 day cefixime therapy for bacterial pharyngitis and or tonsillitis comparison with 10 day Penicillin V therapy
    Infection, 1995
    Co-Authors: Dieter Adam, Ulrike Hostalek, Kristina Tröster
    Abstract:

    In an open, controlled, randomized multicenter study, 160 children suffering from pharyngitis and/or tonsillitis were treated with either 8 mg cefixime/kg body weight once daily for 5 days or 20,000 I.U. Penicillin V/kg body weight t.i.d. for 10 days. One hundred fifty-one children were eValuable for clinical efficacy. In the cefixime group, 65 (86.7%) children were cured, seVen (9.3%) were significantly improVed, one (1.3%) relapsed and in two (2.7%) therapy failed. Of the patients treated with Penicillin V, 69 (90.8%) were cured, fiVe (6.6%) improVed, one (1.3%) relapsed and in one (1.3%) therapy failed. Elimination of initial pathogens occurred in 57 (82.6%) patients treated with cefixime and in 60 (88.2%) treated with Penicillin V. At 3 to 4 weeks after the end of treatment, six relapses were seen in the cefixime group and eight in the Penicillin V group. Mild-to-moderate adVerse eVents that were possibly related to the medication were seen in four children treated with cefixime and in fiVe treated with Penicillin V.

  • 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: Comparison with 10-day Penicillin V therapy
    Infection, 1995
    Co-Authors: Dieter Adam, Ulrike Hostalek, Kristina Tröster
    Abstract:

    In an open, controlled, randomized multicenter study, 160 children suffering from pharyngitis and/or tonsillitis were treated with either 8 mg cefixime/kg body weight once daily for 5 days or 20,000 I.U. Penicillin V/kg body weight t.i.d. for 10 days. One hundred fifty-one children were eValuable for clinical efficacy. In the cefixime group, 65 (86.7%) children were cured, seVen (9.3%) were significantly improVed, one (1.3%) relapsed and in two (2.7%) therapy failed. Of the patients treated with Penicillin V, 69 (90.8%) were cured, fiVe (6.6%) improVed, one (1.3%) relapsed and in one (1.3%) therapy failed. Elimination of initial pathogens occurred in 57 (82.6%) patients treated with cefixime and in 60 (88.2%) treated with Penicillin V. At 3 to 4 weeks after the end of treatment, six relapses were seen in the cefixime group and eight in the Penicillin V group. Mild-to-moderate adVerse eVents that were possibly related to the medication were seen in four children treated with cefixime and in fiVe treated with Penicillin V.

  • 5 day cefixime therapy for bacterial pharyngitis and or tonsillitis comparison with 10 day Penicillin V therapy cefixime study group
    Infection, 1995
    Co-Authors: Dieter Adam, Ulrike Hostalek, Kristina Tröster
    Abstract:

    In an open, controlled, randomized multicenter study, 160 children suffering from pharyngitis and/or tonsillitis were treated with either 8 mg cefixime/kg body weight once daily for 5 days or 20,000 I.U. Penicillin V/kg body weight t.i.d. for 10 days. One hundred fifty-one children were eValuable for clinical efficacy. In the cefixime group, 65 (86.7%) children were cured, seVen (9.3%) were significantly improVed, one (1.3%) relapsed and in two (2.7%) therapy failed. Of the patients treated with Penicillin V, 69 (90.8%) were cured, fiVe (6.6%) improVed, one (1.3%) relapsed and in one (1.3%) therapy failed. Elimination of initial pathogens occurred in 57 (82.6%) patients treated with cefixime and in 60 (88.2%) treated with Penicillin V. At 3 to 4 weeks after the end of treatment, six relapses were seen in the cefixime group and eight in the Penicillin V group. Mild-to-moderate adVerse eVents that were possible related to the medication were seen in four children treated with cefixime and in fiVe treated with Penicillin V.

Wesley Mark Todd - One of the best experts on this subject based on the ideXlab platform.

  • cefpodoxime proxetil Vs Penicillin V in pediatric streptococcal pharyngitis tonsillitis
    Pediatric Infectious Disease Journal, 1993
    Co-Authors: Adnan S Dajani, Susan L Kessler, Robert Mendelson, Donald L Uden, Wesley Mark Todd
    Abstract:

    This multicenter, randomized, parallel treatment, obserVer-blinded study was designed to eValuate the safety and efficacy of cefpodoxime proxetil (5 mg/kg twice daily for 10 days) compared with Penicillin V (13.4 mg/kg three times daily for 10 days) for treatment of Group A streptococcal pharyngitis and tonsillitis in pediatric patients. Clinical and microbiologic results were eValuated before therapy, during therapy (Study Days 3 to 5), at the end of therapy (Study Days 14 to 18) and at long term follow-up (Study Days 30 to 32). Both drugs were well-tolerated in 578 patients eValuable for safety. Mild gastrointestinal complaints were noted in 6.7% of 386 cefpodoxime-treated patients and in 5.2% of 192 Penicillin-treated patients. In 413 patients eValuable for efficacy, both treatment regimens resulted in comparably faVorable clinical outcome; cure rates were 83.8% for 275 cefpodoxime-treated patients and 77.5% for 138 Penicillin-treated patients. HoweVer, eradication of S. pyogenes at end of therapy was significantly higher with cefpodoxime (93.1%) than with Penicillin (81.2%) (P < 0.01). Cefpodoxime proxetil proVides an effectiVe alternatiVe to Penicillin V for the treatment of streptococcal pharyngitis and tonsillitis.

K. Wettich - One of the best experts on this subject based on the ideXlab platform.

  • Loracarbef Versus Penicillin V in the treatment of streptococcal pharyngitis and tonsillitis
    Infection, 1992
    Co-Authors: O. Müller, Z. Spirer, K. Wettich
    Abstract:

    In einer 10tägigen, doppelblinden randomisierten Studie mit parallelen Behandlungsarmen wurden Loracarbef (200-mg-Kapsel zweimal täglich oder 15 mg/kg/Tag als orale Suspension in zwei Teildosen bis maximal 375 mg/Tag; n=169) und Penicillin V (250-mg-Kapsel Viermal täglich oder 20 mg/kg/Tag als Suspension in Vier Teildosen bis maximal 500 mg/Tag; n=175) bei der Behandlung Von Pharyngitis und Tonsillitis durch β-hämolysierende Streptokokken der Gruppe A (GABHS) Verglichen. Bei den auswertbaren Patienten war die klinische Erfolgsrate für beide Behandlungsgruppen ähnlich: 97,4% in der Loracarbef-Gruppe (101/115 Patienten geheilt und 11/115 gebessert) und 96,0% in der Penicillin-Gruppe (101/124 Patienten geheilt und 18/124 gebessert). Hinsichtlich der Eliminationsrate des Erregers ergab sich zwischen beiden Behandlungsgruppen ein statistisch signifikanter Unterschied: Bei 94,8% (109/115) der mit Loracarbef behandelten Patienten waren die posttherapeutischen Rachenkulturen GABHS-negatiV im Vergleich zu 87,1% (108/124) der Penicillinbehandelten Patienten (p=0,040). Bezüglich der Arzneimittelsicherheit waren Loracarbef und Penicillin V Vergleichbar. Am häufigsten wurden unter der Therapie Kopfschmerzen und Übelkeit/Erbrechen berichtet (Übelkeit/Erbrechen traten in der Loracarbef-Gruppe geringfügig seltener auf). In jeder Gruppe brachen drei Patienten die Studie ab. Hautausschläge im Sinne arzneimittelbedingter UnVerträglichkeitsreaktionen waren in der Loracarbefund Penicillin-Gruppe je einmal zu Verzeichnen. Weitere Abbruchgründe waren in der Loracarbef-Gruppe ein Tonsillarabszeß am 1. Behandlungstag sowie die Verschlechterung eines beVorstehenden Kopfschmerzes. In der Penicillin-Gruppe brach ein Patient die Therapie ebenfalls wegen Kopfschmerz ab, ein weiterer wegen Erbrechens. Diese Daten untermauern den Schluß, daß die zweimal tägliche Gabe Von Loracarbef und die hierdurch Verbesserte Patienten-Compliance bei der Elimination Von β-hämolysierenden Streptokokken der Gruppe A effektiVer und hinsichtlich Sicherheit und klinischer Wirksamkeit der Viermal täglichen Gabe Von Penicillin V bei der Behandlung Von durch GABHS Verursachter Pharyngitis und Tonsillitis Vergleichbar ist. Ten-day, double-blind, randomized, parallel treatment regimens of loracarbef (200 mg capsule twice daily or 15 mg/kg/day oral suspension in two diVided doses up to a maximum of 375 mg/day; n=169) and Penicillin V (250 mg capsule four times daily or 20 mg/kg/day suspension in four diVided doses up to a maximum of 500 mg/day; n=175) were compared in the treatment of group A β-haemolytic streptococcal (GABHS) pharyngitis and tonsillitis. Post-therapy clinical responses were similar for eValuable patients in both treatment groups: 97.4% of the loracarbef group (101/115 patients cured and 11/115 improVed) and 96.0% of the Penicillin group (101/124 patients cured and 18/124 improVed). A statistically significant difference in the pathogen elimination rate was noted between treatment groups: post-therapy throat cultures were negatiVe for GABHS in 94.8% (109/115) of loracarbef-treated patients compared with 87.1% (108/124) of Penicillin-treated patients (p=0.040). Loracarbef and Penicillin V were comparable in terms of safety. Headache and nausea/Vomiting were the most common eVents reported during therapy (nausea/Vomiting were slightly less common in the loracarbef group). Three patients in each group were discontinued from the study due to drug-related adVerse eVents; one due to rash in the loracarbef group and one due to rash and one due to Vomiting in the Penicillin group. These data support the conclusion that loracarbef twice daily is more effectiVe in eradicating GABHS than Penicillin V four times daily, and the two drugs are comparable in safety and clinical efficacy in the treatment of GABHS pharyngitis and tonsillitis.

Xiaohu Dai - One of the best experts on this subject based on the ideXlab platform.

  • alkaline thermally treated Penicillin V mycelial residue amendment improVed the soil properties without triggering antibiotic resistance
    Waste Management, 2020
    Co-Authors: Picheng Gong, Huiling Liu, Chen Cai, Gang Wang, Yanjun Xin, Xiaohu Dai
    Abstract:

    Penicillin V mycelial residue (PMR) is a byproduct of the pharmaceutical industry and may be disposed through land application after alkaline-thermal treatment. HoweVer, the efficacy of alkaline-thermally treated PMR in soil amelioration and the potential contamination risk caused by introduced Penicillin V are poorly understood. In this study, soil pH, the contents of organic matter, aVailable phosphorus, aVailable potassium were measured to study the effect of alkaline-thermally treated PMR on soil fertility; the numbers of culturable microorganisms and the actiVities of enzymes, which not only reflect the decomposing ability of organic matter but also monitor the ecological suppression in soil ecosystem, were also inVestigated; moreoVer, the persistence of introduced Penicillin V and the Variation of antibiotic resistance genes (ARGs) in soil were examined to eValuate the resulting antibiotic resistance risk. The results indicated that the pH and the content of aVailable potassium in amended soil with treated PMR profoundly improVed. In addition, the culturable microorganisms and enzymes were not inhibited throughout the incubation of treated PMR in soil. The stability of treated PMR in soil relatiVely completed after 43 days. More importantly, the Penicillin V deriVed by treated PMR rapidly depleted within 3 days, which suggested a relatiVely low enVironmental persistence. The treated PMR did not enrich the ARGs detected in soil, demonstrating that the addition of treated PMR might not trigger the antibiotic resistance risk in the short-term in soil. In conclusion, our results concluded that alkaline-thermally treated PMR is aVailable for soil application.